valerates has been researched along with Disease Models, Animal in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; He, W; Jing, F; Long, T; Qin, G; Zhang, D; Zhang, Y; Zhou, J | 1 |
| Cheung, WH; Chim, YN; Chow, SK; Cui, C; Leung, KS; Shi, L; Wang, J; Wong, RMY; Xu, J; Yao, H | 1 |
| Cui, W; Du, D; Hu, X; Shi, H; Sun, L; Tian, J; Yu, T; Zhang, X | 1 |
| Callahan, LA; Supinski, GS | 1 |
| Chamberlin, AR; Chen, W; Chien, R; Guo, XE; Hu, CM; Kim, Y; Lee, EY; Lee, WH; Lopez, R; Ngo, B; Qiu, XL; Tsai, CY; Wang, YV; Wu, G; Zhu, J | 1 |
| Acksel, C; Boyd, IM; Edens, NK; Garvey, SM; Maynard, J; McCorkle, KW; Russ, DW | 1 |
| Bozkırlı, BO; Ersoy, E; Gündoğdu, RH; Temel, H; Yazgan, A; Yıldırım, Z | 1 |
| Gulley, JM; Haake, RM; Hammerslag, LR; Hankosky, ER; Juraska, JM; Kim, T; Kougias, DG; Ruvola, LA; Sherrill, LK | 1 |
| Fisher, R; Jackson, MJ; Jenner, P; Lees, AJ; Lincoln, L; Neumeyer, J; Rose, S; Sromek, AW | 1 |
| Alway, SE; Edens, N; Hao, Y; Jackson, JR; Pereira, SL; Wang, Y | 1 |
| Fitschen, PJ; Wilson, GJ; Wilson, JM; Wilund, KR | 1 |
| Arjmandi, BH; Grant, SC; Jo, E; Khamoui, AV; Kim, JS; Lee, SR; Lee, WJ; Masad, IS; Panton, LB; Park, BS; Park, YM | 1 |
| Huang, B; Lian, QQ; Liu, MJ; Ni, HD; Sun, JL; Yao, M; Zhou, XY; Zhu, YL | 1 |
| Smith, HJ; Tisdale, MJ; Wyke, SM | 1 |
| Nagao, T; Nakashima, T; Ohshimo, T; Otsuki, S; Sato, M; Tomoda, T; Wake, A | 1 |
| Lai, AA; Levy, RH; Lockard, JS; Patel, IH | 1 |
| Congdon, WC; DuCharme, LL; Levy, RH; Lockard, JS; Patel, IH | 1 |
| Mock, DM; Mock, NI; Weintraub, S | 1 |
| Bronder, B; Loew, H; Ritzerfeld, W | 1 |
2 review(s) available for valerates and Disease Models, Animal
| Article | Year |
|---|---|
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
Topics: Animals; Apomorphine; Aporphines; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Male; MPTP Poisoning; Valerates | 2016 |
Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations.
Topics: Aged; Aging; Animals; Athletes; Dietary Supplements; Disease Models, Animal; Humans; Models, Biological; Muscle Strength; Muscle, Skeletal; Muscular Atrophy; Safety; Signal Transduction; Treatment Outcome; Valerates | 2013 |
17 other study(ies) available for valerates and Disease Models, Animal
| Article | Year |
|---|---|
P2Y12 receptor mediates microglial activation via RhoA/ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine.
Topics: Adenine; Animals; Clopidogrel; Disease Models, Animal; Mice; Microglia; Migraine Disorders; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Trigeminal Nuclei; Valerates | 2019 |
Vibration and β-hydroxy-β-methylbutyrate treatment suppresses intramuscular fat infiltration and adipogenic differentiation in sarcopenic mice.
Topics: Adipogenesis; Animals; Cell Differentiation; Disease Models, Animal; Humans; Injections, Intramuscular; Male; Mice; Sarcopenia; Valerates | 2020 |
P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents.
Topics: Adenine; Animals; Clopidogrel; Disease Models, Animal; Excitatory Postsynaptic Potentials; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Neuralgia; Neurons; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; rho GTP-Binding Proteins; Signal Transduction; Spinal Cord; Spinal Cord Dorsal Horn; Spinal Cord Injuries; Spinal Nerves; Synaptic Transmission; Valerates | 2019 |
β-hydroxy-β-methylbutyrate (HMB) prevents sepsis-induced diaphragm dysfunction in mice.
Topics: Animals; Calpain; Caspase 3; Diaphragm; Disease Models, Animal; eIF-2 Kinase; Lipopolysaccharides; Male; Mice; Muscle Strength; Muscle Weakness; Neuromuscular Agents; Organ Size; Phosphorylation; Proteasome Endopeptidase Complex; Sepsis; Valerates | 2014 |
Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.
Topics: Animals; Benzamides; Binding Sites; Cell Line, Tumor; Cytoskeletal Proteins; Disease Models, Animal; Disease Progression; Gene Expression; Heterografts; Humans; Indoles; Inhibitory Concentration 50; Mitosis; Models, Molecular; Molecular Conformation; Neoplasms; NIMA-Related Kinases; Nuclear Proteins; Phosphorylation; Prognosis; Protein Binding; Protein Serine-Threonine Kinases; Proteolysis; Thiazoles; Valerates | 2015 |
Dietary HMB and β-alanine co-supplementation does not improve in situ muscle function in sedentary, aged male rats.
Topics: Age Factors; Aging; Animals; Autophagy; beta-Alanine; Biomarkers; Dietary Supplements; Disease Models, Animal; Male; Muscle Contraction; Muscle Fatigue; Muscle Proteins; Muscle Strength; Muscle, Skeletal; Phosphorylation; Proteolysis; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Sarcopenia; Sedentary Behavior; Skeletal Muscle Myosins; Time Factors; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Valerates | 2015 |
Mixture of Arginine, Glutamine, and β-hydroxy-β-methyl Butyrate Enhances the Healing of Ischemic Wounds in Rats.
Topics: Animals; Arginine; Collagen; Disease Models, Animal; Glutamine; Hydroxyproline; Ischemia; Rats; Rats, Wistar; Valerates; Wound Healing | 2017 |
Effects of β-hydroxy-β-methyl butyrate on working memory and cognitive flexibility in an animal model of aging.
Topics: Aging; Animals; Cognition; Dietary Supplements; Disease Models, Animal; Female; Male; Memory, Short-Term; Rats; Rats, Long-Evans; Valerates | 2017 |
β-Hydroxy-β-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats.
Topics: Aging; Analysis of Variance; Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Chi-Square Distribution; Crosses, Genetic; Disease Models, Animal; Hindlimb Suspension; In Situ Nick-End Labeling; Isometric Contraction; Male; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Muscular Atrophy; Organ Size; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred BN; Rats, Inbred F344; Recovery of Function; Valerates | 2011 |
β-hydroxy-β-methylbutyrate did not enhance high intensity resistance training-induced improvements in myofiber dimensions and myogenic capacity in aged female rats.
Topics: Aging; Animals; Body Weight; Disease Models, Animal; Female; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Valerates | 2012 |
[Influence of P2Y12 receptor inhibitor on pain threshold and spinal p38MAPK in rat bone cancer pain model].
Topics: Adenine; Animals; Bone Neoplasms; Disease Models, Animal; Female; p38 Mitogen-Activated Protein Kinases; Pain; Pain Threshold; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spinal Cord; Valerates | 2012 |
Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
Topics: Animals; Arachidonic Acid; Blood Proteins; Disease Models, Animal; Eicosapentaenoic Acid; Mice; Muscle Fibers, Skeletal; Muscle Proteins; Neoplasms, Experimental; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteoglycans; Signal Transduction; Ubiquitin; Valerates; Weight Loss | 2004 |
[Prophylactic and anticonvulsive effects of di--N--propylacetate examined in kindling cat preparations (author's transl)].
Topics: Amygdala; Animals; Cats; Disease Models, Animal; Drug Evaluation, Preclinical; Electric Stimulation; Electroencephalography; Seizures; Temporal Lobe; Valerates; Valproic Acid | 1977 |
Efficacy testing of valproic acid compared to ethosuximide in monkey model: I. Dosage regimen design in the presence of diurnal oscillations.
Topics: Animals; Biopharmaceutics; Circadian Rhythm; Disease Models, Animal; Ethosuximide; Haplorhini; Macaca mulatta; Male; Seizures; Valerates; Valproic Acid | 1977 |
Efficacy testing of valproic acid compared to ethosuximide in monkey model: II. Seizure, EEG, and diurnal variations.
Topics: Animals; Circadian Rhythm; Disease Models, Animal; Electroencephalography; Ethosuximide; Haplorhini; Macaca mulatta; Male; Seizures; Valerates; Valproic Acid | 1977 |
Abnormal organic aciduria in biotin deficiency: the rat is similar to the human.
Topics: Animals; Biotin; Disease Models, Animal; Gas Chromatography-Mass Spectrometry; Glycine; Male; Random Allocation; Rats; Rats, Inbred Strains; Valerates | 1988 |
[Studies on the hormonal facilitation of experimental Escherichia-coli-pyelonephritis in the rat].
Topics: Animals; Caproates; Disease Models, Animal; Escherichia coli Infections; Estradiol; Female; Hydroxyprogesterones; Injections, Intramuscular; Kidney; Pyelonephritis; Rats; Species Specificity; Undecylenic Acids; Valerates | 1973 |